冠状动脉疾病患者糖代谢异常筛查与危险因素管理:ESC EORP EUROASPIRE V研究
ESC EORP EUROASPIRE V(2016-2017)纳入27国8261例18-80岁冠心病患者,对血糖状态未知者行口服葡萄糖耐量试验(OGTT)和糖化血红蛋白检测。结果发现仅约三分之一患者糖代谢完全正常;若不进行OGTT,30%的2型糖尿病和70%的糖耐量受损(IGT)患者将不被发现。已知糖尿病者仅31%被建议就诊糖尿病门诊、24%实际就诊;糖代谢异常者仅58%处方全部心脏保护药物。
要点
- 血糖状态未知的冠心病患者中41.1%经OGTT检出糖代谢异常。
- 未行OGTT则30%的2型糖尿病和70%的IGT患者漏诊。
- 已知糖尿病者仅31%被建议去糖尿病门诊,24%实际就诊。
核心结论
- 冠心病合并糖代谢异常患者的筛查和管理亟需紧急改进,以期大幅降低心血管事件复发和糖尿病并发症风险并延长预期寿命。
研究设计与样本
- 欧洲心脏病学会欧洲观察性研究项目(ESC EORP)EUROASPIRE V(2016-2017)调查,纳入27个国家8261例18-80岁冠心病患者;血糖状态未知者接受OGTT和糖化血红蛋白A1c检测,并调查生活方式、危险因素和药物治疗。
主要发现
- 2452例(29.7%)患者为已知糖尿病;4440例血糖状态未知者行OGTT,其中41.1%为糖代谢异常。
- 若不进行OGTT,30%的2型糖尿病患者和70%的IGT患者将不被检出;筛查后糖代谢异常的真实比例较自我报告几乎翻倍。
- 仅约三分之一的冠心病患者糖代谢完全正常。
- 已知糖尿病患者中31%被建议至糖尿病门诊就诊,仅24%实际就诊。
- 仅58%的糖代谢异常患者处方了全部心脏保护药物;钠-葡萄糖协同转运蛋白2抑制剂使用率3%,胰高血糖素样肽1受体激动剂使用率1%。
关键数值与推荐
- 本调查中糖代谢异常定义为糖耐量受损(IGT)或2型糖尿病。
- 若血糖状态未知,患者接受OGTT和糖化血红蛋白A1c检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dysglycemia, in this survey defined as impaired glucose tolerance (IGT) or type 2 diabetes, is common in patients with coronary artery disease (CAD) and associated with an unfavorable prognosis. This European survey investigated dysglycemia screening and risk factor management of patients with CAD in relation to standards of European guidelines for cardiovascular subjects. RESEARCH DESIGN AND METHODS: The European Society of Cardiology's European Observational Research Programme (ESC EORP) European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V (2016-2017) included 8,261 CAD patients, aged 18-80 years, from 27 countries. If the glycemic state was unknown, patients underwent an oral glucose tolerance test (OGTT) and measurement of glycated hemoglobin A1c. Lifestyle, risk factors, and pharmacological management were investigated. RESULTS: A total of 2,452 patients (29.7%) had known diabetes. OGTT was performed in 4,440 patients with unknown glycemic state, of whom 41.1% were dysglycemic. Without the OGTT, 30% of patients with type 2 diabetes and 70% of those with IGT would not have been detected. The presence of dysglycemia almost doubled from that self-reported to the true proportion after screening. Only approximately one-third of all coronary patients had completely normal glucose metabolism. Of patients with known diabetes, 31% had been advised to attend a diabetes clinic, and only 24% attended. Only 58% of dysglycemic patients were prescribed all cardioprotective drugs, and use of sodium-glucose cotransporter 2 inhibitors (3%) or glucagon-like peptide 1 receptor agonists (1%) was small. CONCLUSIONS: Urgent action is required for both screening and management of patients with CAD and dysglycemia, in the expectation of a substantial reduction in risk of further cardiovascular events and in complications of diabetes, as well as longer life expectancy.
引用
- Ferrannini G, De Bacquer D, De Backer G, et al. Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Diabetes Care. 2020. PMID: 32079627. doi:10.2337/dc19-2165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。